AUA 2015 - Voiding Dysfunctions

REVIEW UroToday

Viewing 1-14 of 14 articles

#AUA15 - Point-Counterpoint: Refractory overactive bladder (OAB) with pelvic organ prolapse (POP) - Session Highlights

#AUA15 - Durable reductions in urinary incontinence with long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: Final results of 3.5-year study - Session Highlights

#AUA15 - The severity of bowel dysfunction in patients with neurogenic bladder - Session Highlights

#AUA15 - Medical complications and urological surveillance in the United States adult spina bifida population - Session Highlights

#AUA15 - Crossfire: Controversies in Urology: Neuromodulation should be the first choice over botulinum toxin for idiopathic detrusor overactivity - Session Highlights

#AUA15 - Best of Abstracts: Is retropubic mid-urethral sling safe and effective for patients with Valsalva voiding? - Session Highlights

#AUA15 - Utilizing more restrictive criteria for obtaining urodynamics in women with multiple sclerosis does not result in more worrisome findings - Session Highlights

#AUA15 - Intradetrusor botulinum toxin for the management of impaired bladder compliance refractory to anti-cholinergic drugs - Session Highlights

#AUA15 - Does asymptomatic bacteriuria increase the risk of urosepsis or modify intra-detrusor botulinum toxin A (BoNTA) efficacy? - Session Highlights

#AUA15 - Urological surveillance and medical complications after spinal cord injury in the United States - Session Highlights

#AUA15 - Effect of onabotulinumtoxinA treatment for neurogenic detrusor overactivity on the prevention of autonomic dysreflexia - Session Highlights

#AUA15 - Long-term efficacy and safety of onobotulinumtoxinA in patients with neurogenic detrusor overactivity: Analysis among patients who completed 4 years of treatment - Session Highlights

#AUA15 - Evidence demonstrates long-term efficacy of botulinum toxin A treatment for neurogenic and non-neurogenic overactive bladder - Session Highlights

#AUA15 - A decade of pharmacotherapy for OAB: What have we learned? - Session Highlights